Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease~* Measurable disease~* Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry~Exclusion Criteria:~* Prior chemotherapy for metastatic disease~* HER2 positive and/or hormonal receptor positive

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Association bevacizumab paclitaxel capecitabine breast cancer (Type: EXPERIMENTAL): * bevacizumab 10 mg/kg in IV, D1 and D15~* paclitaxel 80mg/m2 in IV, D1 to D8 and D15~* capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3

Based on this trial design, predict the completion outcome and termination type (if applicable).